Skip to main content
OCGN
NASDAQ Life Sciences

Ocugen 公布 Q4 每股收益为 -$0.06，运营利润为负

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$1.9
Mkt Cap
$609.872M
52W Low
$0.515
52W High
$1.96
Market data snapshot near publication time

summarizeSummary

Ocugen 公布 Q4 每股收益为 -$0.06，运营费用为 1680.2 万美元，营业利润为 -1699.5 万美元，净利润为 -1770.6 万美元。这份财务更新为我们提供了公司近期发布积极临床消息后的现金消耗率一瞥。持续的负盈利和运营利润为负凸显了处于开发阶段的生物技术公司面临的持续财务挑战。交易者将在公司的现金储备和未来融资需求的背景下评估这些结果，特别是公司推进其临床管道的同时。

在该公告发布时，OCGN的交易价格为$1.90，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6.1亿。 52周交易区间为$0.52至$1.96。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed OCGN - Latest Insights

OCGN
Apr 28, 2026, 7:01 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Ocugen's Annual Meeting Proxy Omits Reverse Stock Split Proposal
Sentiment: Negative
View Wiseek Article
OCGN
Apr 20, 2026, 5:18 PM EDT
Filing Type: PRER14A
Importance Score:
8
Ocugen Amends Reverse Stock Split Proposal, Lowers Minimum Ratio to 1:2 Amidst Going Concern
Sentiment: Negative
View Wiseek Article
OCGN
Apr 17, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Ocugen Seeks Shareholder Approval for Reverse Stock Split Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
OCGN
Mar 27, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Ocugen Completes Phase 3 Enrollment for Two Gene Therapies, Targets Three BLA Submissions by 2028
Sentiment: Positive
View Wiseek Article
OCGN
Mar 26, 2026, 7:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Details Positive OCU410 Phase 2 Data & Comprehensive Gene Therapy Pipeline in Investor Presentation
Sentiment: Positive
View Wiseek Article
OCGN
Mar 24, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
OCU410 Gene Therapy Reduces Geographic Atrophy Lesion Growth by 31% in Positive Phase 2 Data; Ocugen to Advance to Phase 3
Sentiment: Positive
View Wiseek Article
OCGN
Mar 23, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Ocugen to Present Phase 2 OCU410 Gene Therapy Data for Geographic Atrophy on March 24
Sentiment: Neutral
View Wiseek Article
OCGN
Mar 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Secures $15M from Warrant Exercise, Extends Cash Runway Amidst Going Concern
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
9
Ocugen Reports Positive OCU410 Phase 2 Data, Secures Cash Runway Beyond 2026
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 11:38 AM EST
Filing Type: 10-K
Importance Score:
9
Ocugen's 10-K Reveals Going Concern, Limited Cash Runway, and Ongoing Legal Battle Over Share Count
Sentiment: Negative
View Wiseek Article